BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Eskitis Institute At Griffith University Has Chosen Evotec Technologies GmbH (DX:EVT)' Opera As A HCS Platform


6/28/2006 11:37:57 AM

HAMBURG, Germany and BRISBANE, Australia, June 28 /PRNewswire/ -- Evotec Technologies GmbH, a supplier of innovative tools and technologies for life sciences and pharmaceutical drug discovery, and the Eskitis Institute, Griffith University, today announced the installation of an Opera(TM) system as a platform to provide Eskitis' with high-content screening (HCS).

With almost 40 installations today the Opera has become the most prominent system for combining high-throughput screening with high content analysis. The Opera combines the precision of confocal microscopy with the speed of primary screening instrumentation.

"We are extremely proud to be chosen by Eskitis as technology provider. We see an increasing demand for fully automated microscopy in academia research to cope with the high throughput experimentation requirements of modern cell biology research. The Opera is the ideal tool for such purpose because it provides true confocality and the desired speed plus great flexibility with respect to options and upgrades, e.g. excitation / emission combinations, imaging magnification, on-board dispensing, environmental control, or plate handling," stated Dr Guenter Bauer, CBO at Evotec Technologies GmbH.

"The Opera will further enhance the capabilities of Eskitis in the area of high content cell biology by providing a platform that will enable research into cellular functions at a speed and throughput not previously available to Australian researchers. It is also an important advance in the drug discovery process as it is able to provide multiple readouts on how a potential drug may effect the growth and function of a cell," comments Professor Ron Quinn, Professor & Director of Eskitis Institute for Cell and Molecular Therapies, Griffith University.

Contact: Evotec Technologies GmbH Dr. Gunter Bauer Schnackenburgallee 114 22525 Hamburg, Germany Phone: +49-40-56081-321 E-mail: guenter.bauer@evotec-technologies.com

Evotec Technologies GmbH

CONTACT: Evotec Technologies GmbH, Dr. Gunter Bauer, Phone:+49-40-56081-321, E-mail: guenter.bauer@evotec-technologies.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES